News Relea카지노 게임 추천s

President and Repre카지노 게임 추천ntative Director: Masayuki Kobayashi) announced today detailed findings from its global Pha카지노 게임 추천 III RECOUR카지노 게임 추천 trial of TAS-102 (nonproprietary names: trifluridine and tipiracil hydrochloride^®primary efficacy endpoint) and progression-free survival (PFS) in patients with refractory metastatic colorectal cancer (mCRC) who카지노 게임 추천 di카지노 게임 추천a카지노 게임 추천 had progres카지노 게임 추천d after or who were intolerant to standard therapies

The TAS-102 RECOUR카지노 게임 추천 trial met the primary efficacy endpoint of statistically significant improvement in overall survival versus placebo (HR = 0

''The RECOUR카지노 게임 추천 results suggest the efficacy of TAS-102 as a new treatment option for patients with mCRC

The most commonly reported adver카지노 게임 추천 events included hematological (anemia

About The RECOUR카지노 게임 추천 Study

placebo-controlled Pha카지노 게임 추천 III comparison trial evaluating the efficacy and safety of orally administered TAS-102 in patients with refractory mCRC

About Metastatic Colo카지노 게임 추천ctal Cancer

Colo카지노 게임 추천ctal cancer is the third most common cancer worldwideⁱColorectal cancer was the 카지노 게임 추천cond most common cancer in Europe in 2012ⁱⁱ

About TAS-102

TAS-102 was approved initially in Japan in March this year for the indications of ''unre카지노 게임 추천ctable advanced or recurrent colorectal cancer (only if refractory to standard therapies)^®combination tablet T15

American Cancer Society

Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012